SAGE Therapeutics (NASDAQ:SAGE)‘s stock had its “buy” rating reaffirmed by Cowen in a report issued on Tuesday, March 20th. They currently have a $202.00 target price on the biopharmaceutical company’s stock. Cowen’s price objective would indicate a potential upside of 19.33% from the stock’s current price.
Several other research firms also recently commented on SAGE. BidaskClub upgraded SAGE Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 3rd. JPMorgan Chase reiterated a “buy” rating on shares of SAGE Therapeutics in a research note on Wednesday, January 10th. Stifel Nicolaus reiterated a “buy” rating and issued a $198.00 price objective on shares of SAGE Therapeutics in a research note on Friday, December 8th. Morgan Stanley assumed coverage on SAGE Therapeutics in a research note on Monday, February 26th. They issued an “overweight” rating and a $225.00 price objective on the stock. Finally, SunTrust Banks upped their price objective on SAGE Therapeutics to $203.00 and gave the company a “buy” rating in a research note on Wednesday, February 28th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and fourteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $185.20.
SAGE Therapeutics stock traded up $2.26 during trading on Tuesday, hitting $169.28. The stock had a trading volume of 400,938 shares, compared to its average volume of 580,067. SAGE Therapeutics has a 1 year low of $59.57 and a 1 year high of $195.97. The company has a market cap of $7,753.87, a price-to-earnings ratio of -23.72 and a beta of 3.03.
SAGE Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($1.75) EPS for the quarter, beating the consensus estimate of ($1.98) by $0.23. During the same period in the previous year, the company posted ($1.50) earnings per share. equities analysts anticipate that SAGE Therapeutics will post -8.34 earnings per share for the current year.
In other SAGE Therapeutics news, Director Steven M. Paul sold 58,139 shares of the stock in a transaction on Tuesday, March 6th. The stock was sold at an average price of $172.00, for a total transaction of $9,999,908.00. Following the sale, the director now owns 632,712 shares in the company, valued at $108,826,464. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 6.10% of the company’s stock.
Large investors have recently bought and sold shares of the business. Oppenheimer Asset Management Inc. increased its holdings in shares of SAGE Therapeutics by 412.9% in the third quarter. Oppenheimer Asset Management Inc. now owns 1,944 shares of the biopharmaceutical company’s stock worth $122,000 after purchasing an additional 1,565 shares during the period. Bessemer Group Inc. bought a new position in shares of SAGE Therapeutics in the third quarter worth $141,000. Fortaleza Asset Management Inc. bought a new position in shares of SAGE Therapeutics in the fourth quarter worth $167,000. First Mercantile Trust Co. bought a new position in shares of SAGE Therapeutics in the fourth quarter worth $169,000. Finally, Envestnet Asset Management Inc. increased its holdings in shares of SAGE Therapeutics by 70.7% in the third quarter. Envestnet Asset Management Inc. now owns 2,906 shares of the biopharmaceutical company’s stock worth $182,000 after purchasing an additional 1,204 shares during the period. Hedge funds and other institutional investors own 96.29% of the company’s stock.
WARNING: This story was originally posted by Macon Daily and is the property of of Macon Daily. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://macondaily.com/2018/04/12/sage-therapeutics-sage-buy-rating-reaffirmed-at-cowen-updated-updated-updated.html.
About SAGE Therapeutics
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.